Table 1.
Characteristics of patients with and without cardiotoxicity.
| Cases (n = 78) | Controls (n = 99) | P | |
|---|---|---|---|
| Age (years) | 60.9 ± 9.7 | 58.2 ± 11.4 | 0.095 |
| BMI (kg/m2) | 26.4 ± 4.3 | 27.1 ± 4.7 | 0.340 |
| Hypertension n (%) | 46 (59.0) | 48 (48.5) | 0.165 |
| Diabetes n (%) | 8 (10.3) | 5 (5.1) | 0.187 |
| Dyslipidemia n (%) | 23 (29.5) | 20 (20.2) | 0.153 |
| Coronary artery disease n (%) | 1 (1.3) | 0 (0.0) | 0.259 |
| Family history of heart disease n (%) | 31 (39.7) | 20 (20.2) | 0.004 |
| Genotype, n (%) | 0.934 | ||
| A/A | 48 (61.5) | 63 (63.6) | |
| A/G | 27 (34.6) | 33 (33.3) | |
| G/G | 3 (3.8) | 3 (3.0) | |
| Left breast involvement n (%) | 47 (60.3) | 36 (36.4) | 0.002 |
| Grade, n (%) | 0.382 | ||
| 1 | 0 (0.0) | 2 (2.0) | |
| 2 | 32 (41.0) | 44 (44.4) | |
| 3 | 53 (59.0) | 53 (53.5) | |
| T status, n (%) | 0.707 | ||
| 1 | 34 (43.6) | 48 (48.5) | |
| 2 | 37 (47.4) | 46 (46.5) | |
| 3 | 5 (6.4) | 3 (3.0) | |
| 4 | 2 (2.6) | 2 (2.0) | |
| N status, n (%) | 0.018 | ||
| 0 | 41 (52.6) | 54 (54.5) | |
| 1 | 17 (21.8) | 31 (31.3) | |
| 2 | 11 (14.1) | 13 (13.1) | |
| 3 | 9 (11.5) | 1 (1.0) | |
| ER, n (%) | 51 (65.4) | 60 (60.6) | 0.514 |
| PR, n (%) | 48 (61.5) | 50 (50.5) | 0.425 |
| HER2 (ISH positive), n (%) | 11 (14.1) | 15 (15.2) | 0.845 |
| HER2 (IHC positive), n (%) | 67 (85.9) | 84 (84.8) | 0.845 |
| Radiotherapy, n (%) | 65 (83.3) | 75 (75.8) | 0.218 |
| Chemotherapy protocol, n (%) | 0.267 | ||
| 4th cycle of anthracycline | 22 (28.2) | 22 (18.2) | |
| 6th cycle of anthracycline | 50 (62.8) | 63 (62.6) | |
| Without anthracyclines, n (%) | 6 (7.7) | 12 (13.1) | 0.333 |
| ACx4 protocol, n (%) | 0.170 | ||
| ACx4 + PT | 17 (81.0) | 11 (61.1) | |
| ACx4 + Px4 | 5 (19.0) | 7 (38.9) |
BMI, Body Mass Index; HER2, Human epidermal growth factor receptor 2; A, Adenin; G, guanine; T, Tumor; N, Node; ER, Estrogen Receptors; PR, Progesterone Receptors; ISH, In situ Hybridization; IHC, Immunohistochemistry; AC, Doxorubicin + Cyclophosphamide; PT, Paclitaxel + Trastuzumab; P, Paclitaxel, P value was calculated with one-way analysis of variance (ANOVA).